{"protocolSection": {"identificationModule": {"nctId": "NCT01225549", "orgStudyIdInfo": {"id": "D2340C00005"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen", "officialTitle": "A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen", "acronym": "Allergen"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-11"}, "primaryCompletionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-15", "studyFirstSubmitQcDate": "2010-10-20", "studyFirstPostDateStruct": {"date": "2010-10-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-01-15", "resultsFirstSubmitQcDate": "2015-03-31", "resultsFirstPostDateStruct": {"date": "2015-04-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-31", "lastUpdatePostDateStruct": {"date": "2015-04-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Allergen Challenge", "Asthma", "Inhaled selective glucocorticoid receptor agonist (iSEGRA)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 27, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "AZD5423 75ug", "interventionNames": ["Drug: AZD5423", "Drug: Placebo"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "AZD5423 300ug", "interventionNames": ["Drug: AZD5423", "Drug: Placebo"]}, {"label": "3", "type": "ACTIVE_COMPARATOR", "description": "Budesonide 200 microgram", "interventionNames": ["Drug: Budesonide 200 microgram", "Drug: Placebo"]}, {"label": "4", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "AZD5423", "description": "Suspension for nebulisation once daily 7 days", "armGroupLabels": ["1", "2"]}, {"type": "DRUG", "name": "Budesonide 200 microgram", "description": "Dry powder for inhalation twice daily 7 days", "armGroupLabels": ["3"], "otherNames": ["Pulmicort"]}, {"type": "DRUG", "name": "Placebo", "description": "Solution for nebulisation once daily 7 days", "armGroupLabels": ["3", "4"]}, {"type": "DRUG", "name": "Placebo", "description": "Solution for nebulisation once daily 7 days", "armGroupLabels": ["1", "2", "4"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1", "description": "LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1", "timeFrame": "From Randomization to end of treatment"}], "secondaryOutcomes": [{"measure": "Early Allergic Response (EAR) by Assessment of Minimum Percentage of FEV1 0-3 h Post Allergen Challenge", "description": "Minimum Percentage of FEV1 over 0 to 3 hours post allergen challenge compared to pre allergen challenge FEV1", "timeFrame": "From Randomization to end of treatment"}, {"measure": "Area Under the Curve (AUC) for FEV1 Over 0-3 and 3-7 h Post Allergen Challenge", "description": "AUC was assessed as average percentage of FEV1 remaining 0 to 3 hours and 3 to 7 hours post allergen challenge compared to pre allergen challenge FEV1", "timeFrame": "From Randomization to end of treatment"}, {"measure": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "timeFrame": "Day 1 (pre-dose)"}, {"measure": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "timeFrame": "Day 5 ([post-dose] pre allergen challenge)"}, {"measure": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "timeFrame": "Day 7 ([post-dose] 24 hours post allergen challenge)"}, {"measure": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "timeFrame": "Day 5 (post dose)"}, {"measure": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "timeFrame": "Day 6 ([post dose] 7 hours post allergen challenge)"}, {"measure": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "timeFrame": "Day 7 ([post dose] 24 hours post allergen challenge)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 18-60 years of age\n* Pre-bronchodilatory FEV1 \u226570% of predicted normal allergic asthmatic with a history of episodic wheeze\n* Positive allergen induced early and late airway bronchoconstriction showing \u2265 20% fall in FEV1 for the early and \u2265 15% for the late response\n* Positive skin prick test to common aeroallergens\n\nExclusion Criteria:\n\n* Any clinically significant disease or disorder\n* Any clinically relevant abnormal finding at screening examinations\n* Smoker or ex-smoker who has stopped smoking \\< 12 months prior to study start\n* Worsening of asthma or respiratory infection within 6 weeks from visit 1\n* Allergen-specific immunotherapy within 6 months prior to visit 1", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Christer Hultquist", "affiliation": "AstraZeneca R&D, M\u00f6lndal, Sweden", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Saskatoon", "state": "Saskatchewan", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"references": [{"pmid": "25473939", "type": "DERIVED", "citation": "Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Killian KJ, Davis BE, Deschesnes F, Watson RM, Swystun V, Mardh CK, Wessman P, Jorup C, Aurivillius M, O'Byrne PM. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. doi: 10.1164/rccm.201404-0623OC."}], "seeAlsoLinks": [{"label": "CSR Synopsis", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=203&filename=D2340C00005.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Total 27 patients enrolled, 20 (74.1%) patients were randomised to receive a treatment sequence consisting of 4 different treatment in random order. From 20 randomised patients, 18 (90%) patients completed the study and 2 (10%) patients were withdrawn from the study due to consumption of disallowed medication", "recruitmentDetails": "Patients were enrolled from 4 centres in the AllerGen CIC group in Canada.", "groups": [{"id": "FG000", "title": "ACBP", "description": "AZD5423 75 \u00b5g followed by budesonide 200 \u00b5g bid followed by AZD5423 300 \u00b5g od followed by placebo"}, {"id": "FG001", "title": "APBC", "description": "AZD5423 75 \u00b5g followed by placebo followed by AZD5423 300 \u00b5g od followed by budesonide 200 \u00b5g bid"}, {"id": "FG002", "title": "BACP", "description": "AZD5423 300 \u00b5g od followed by AZD5423 75 \u00b5g followed by budesonide 200 \u00b5g bid followed by placebo"}, {"id": "FG003", "title": "BPCA", "description": "AZD5423 300 \u00b5g od followed by placebo followed by budesonide 200 \u00b5g bid followed by AZD5423 75 \u00b5g"}, {"id": "FG004", "title": "CAPB", "description": "Budesonide 200 \u00b5g bid followed by AZD5423 75 \u00b5g followed by placebo followed by AZD5423 300 \u00b5g od"}, {"id": "FG005", "title": "CBAP", "description": "Budesonide 200 \u00b5g bid followed by AZD5423 300 \u00b5g od followed by AZD5423 75 \u00b5g followed by placebo"}, {"id": "FG006", "title": "CBPA", "description": "Budesonide 200 \u00b5g bid followed by AZD5423 300 \u00b5g od followed by placebo followed by AZD5423 75 \u00b5g"}, {"id": "FG007", "title": "PBAC", "description": "Placebo followed by AZD5423 300 \u00b5g od followed by AZD5423 75 \u00b5g followed by budesonide 200 \u00b5g bid"}, {"id": "FG008", "title": "PCAB", "description": "Placebo followed by budesonide 200 \u00b5g bid followed by AZD5423 75 \u00b5g followed by AZD5423 300 \u00b5g od"}, {"id": "FG009", "title": "PCBA", "description": "Placebo followed by budesonide 200 \u00b5g bid followed by AZD5423 300 \u00b5g od followed by AZD5423 75 \u00b5g"}], "periods": [{"title": "Period 1 - First Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 2 - Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 3 - Second Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 4 - Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Disallowed medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 5 - Third Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 6 - Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Disallowed medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 7 - Fourth Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "3"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Baseline Total", "description": "Total number of patients randomised and treated in the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.6", "lowerLimit": "18", "upperLimit": "60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}]}]}, {"title": "Others", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1", "description": "LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1", "populationDescription": "PD Analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage", "timeFrame": "From Randomization to end of treatment", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90.97", "lowerLimit": "73.20", "upperLimit": "100.00"}, {"groupId": "OG001", "value": "91.32", "lowerLimit": "76.80", "upperLimit": "101.60"}, {"groupId": "OG002", "value": "87.28", "lowerLimit": "56.60", "upperLimit": "103.20"}, {"groupId": "OG003", "value": "85.83", "lowerLimit": "69.60", "upperLimit": "102.80"}]}]}]}, {"type": "SECONDARY", "title": "Early Allergic Response (EAR) by Assessment of Minimum Percentage of FEV1 0-3 h Post Allergen Challenge", "description": "Minimum Percentage of FEV1 over 0 to 3 hours post allergen challenge compared to pre allergen challenge FEV1", "populationDescription": "PD Analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage", "timeFrame": "From Randomization to end of treatment", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "69.75", "lowerLimit": "41.00", "upperLimit": "94.00"}, {"groupId": "OG001", "value": "69.57", "lowerLimit": "41.80", "upperLimit": "92.60"}, {"groupId": "OG002", "value": "67.98", "lowerLimit": "41.60", "upperLimit": "92.40"}, {"groupId": "OG003", "value": "69.30", "lowerLimit": "35.20", "upperLimit": "92.60"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Curve (AUC) for FEV1 Over 0-3 and 3-7 h Post Allergen Challenge", "description": "AUC was assessed as average percentage of FEV1 remaining 0 to 3 hours and 3 to 7 hours post allergen challenge compared to pre allergen challenge FEV1", "populationDescription": "PD Analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage", "timeFrame": "From Randomization to end of treatment", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"title": "AUC over 0-3 (Average EAR)", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.82", "lowerLimit": "64.10", "upperLimit": "95.25"}, {"groupId": "OG001", "value": "83.71", "lowerLimit": "65.70", "upperLimit": "96.68"}, {"groupId": "OG002", "value": "81.90", "lowerLimit": "56.50", "upperLimit": "93.90"}, {"groupId": "OG003", "value": "82.26", "lowerLimit": "57.10", "upperLimit": "97.97"}]}]}, {"title": "AUC over 3-7 (Average LAR)", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.30", "lowerLimit": "87.62", "upperLimit": "104.67"}, {"groupId": "OG001", "value": "96.53", "lowerLimit": "85.70", "upperLimit": "103.93"}, {"groupId": "OG002", "value": "93.39", "lowerLimit": "69.69", "upperLimit": "107.34"}, {"groupId": "OG003", "value": "92.50", "lowerLimit": "80.77", "upperLimit": "106.23"}]}]}]}, {"type": "SECONDARY", "title": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "populationDescription": "PD Analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "mg/mL", "timeFrame": "Day 1 (pre-dose)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.560", "lowerLimit": "0.11", "upperLimit": "32.00"}, {"groupId": "OG001", "value": "1.651", "lowerLimit": "0.14", "upperLimit": "36.80"}, {"groupId": "OG002", "value": "1.688", "lowerLimit": "0.08", "upperLimit": "17.75"}, {"groupId": "OG003", "value": "1.538", "lowerLimit": "0.07", "upperLimit": "53.70"}]}]}]}, {"type": "SECONDARY", "title": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "mg/mL", "timeFrame": "Day 5 ([post-dose] pre allergen challenge)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.755", "lowerLimit": "0.13", "upperLimit": "32.00"}, {"groupId": "OG001", "value": "2.693", "lowerLimit": "0.26", "upperLimit": "64.00"}, {"groupId": "OG002", "value": "2.477", "lowerLimit": "0.19", "upperLimit": "18.70"}, {"groupId": "OG003", "value": "2.034", "lowerLimit": "0.09", "upperLimit": "53.80"}]}]}]}, {"type": "SECONDARY", "title": "Airway Hyperresponsiveness by Assessment of Methacholine PC20", "description": "The methacholine challenge was performed on Day 1 (pre dose), Day 5 (\\[post dose\\] pre AC), and Day 7 (\\[post dose\\] 24 hours post AC)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "mg/mL", "timeFrame": "Day 7 ([post-dose] 24 hours post allergen challenge)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.017", "lowerLimit": "0.21", "upperLimit": "32.00"}, {"groupId": "OG001", "value": "2.007", "lowerLimit": "0.15", "upperLimit": "45.89"}, {"groupId": "OG002", "value": "1.666", "lowerLimit": "0.06", "upperLimit": "17.19"}, {"groupId": "OG003", "value": "1.214", "lowerLimit": "0.06", "upperLimit": "35.10"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "populationDescription": "PD Analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Day 5 (post dose)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.891", "spread": "8.375"}, {"groupId": "OG001", "value": "-3.2", "spread": "9.162"}, {"groupId": "OG002", "value": "-1.825", "spread": "4.342"}, {"groupId": "OG003", "value": "-0.016", "spread": "1.835"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Day 6 ([post dose] 7 hours post allergen challenge)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.633", "spread": "6.011"}, {"groupId": "OG001", "value": "0.592", "spread": "9.658"}, {"groupId": "OG002", "value": "7.500", "spread": "11.800"}, {"groupId": "OG003", "value": "12.333", "spread": "14.260"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Sputum Eosinophils Differentials (Percentage)", "description": "The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 (\\[post dose\\] 7 hours post allergen challenge) and Day 7 (\\[post dose\\] 24 hours post allergen challenge)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Day 7 ([post dose] 24 hours post allergen challenge)", "groups": [{"id": "OG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "200\u00b5g budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence."}, {"id": "OG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.688", "spread": "8.230"}, {"groupId": "OG001", "value": "2.286", "spread": "15.417"}, {"groupId": "OG002", "value": "6.967", "spread": "11.697"}, {"groupId": "OG003", "value": "5.634", "spread": "5.520"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Arm 1 - 75ug AZD5423", "description": "75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 8, "otherNumAtRisk": 19}, {"id": "EG001", "title": "Arm 2 - 300ug AZD5423", "description": "300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 1, "otherNumAtRisk": 19}, {"id": "EG002", "title": "Arm 3 - 2x200ug Budesonide", "description": "2x200ug budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 9, "otherNumAtRisk": 19}, {"id": "EG003", "title": "Arm 4 - Placebo", "description": "Placebo administered in any of the first, second, third or fourth period of a particular sequence.", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 9, "otherNumAtRisk": 20}], "otherEvents": [{"term": "CONJUNCTIVITIS", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ABDOMINAL DISCOMFORT", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "DRY MOUTH", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "DYSPHAGIA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "GASTROOESOPHAGEAL REFLUX DISEASE", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PYREXIA", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "PHARYNGITIS BACTERIAL", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "VIRAL PHARYNGITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "CONTUSION", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "SCRATCH", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "HELICOBACTER TEST POSITIVE", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "MUSCULOSKELETAL CHEST PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "INSOMNIA", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "DYSMENORRHOEA", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "DYSPHONIA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "DYSPNOEA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}, {"term": "NASAL CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 20}]}, {"term": "OROPHARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 20}]}, {"term": "DRUG ERUPTION", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "ERYTHEMA", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 20}]}, {"term": "URTICARIA", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 20}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Of the 27 patients enrolled, 20 (74.1%) patient were randomised to receive a treatment sequence consisting of 4 different treatment in random order. 19 patients completed each individual treatment period and 17 patients completed all 4 treatment"}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "PI shall not publish any results until (i) the date of the first Study results publication, or in case of a Multi-Centre Study the first Multi-Centre Results publication, agreed by the participating sites, and (ii) the end of the eighteen (18) month period following the completion or early termination of the Study at all participating sites."}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M13031", "name": "Oxymetazoline", "relevance": "LOW"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M13561", "name": "Phenylephrine", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}